Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172788 | 0.95 | AOC3 (0.38) | AOC3ALDH1A1CYP3A4CYP2C9TSHR | |
| SCHEMBL5667289 | 0.77 | AOC3 (0.36) | AOC3ALDH1A1SLC6A3SLC6A4NPC1 | |
| SCHEMBL3640169 | 0.76 | AOC3 (0.44) | AOC3ALDH1A1FAAHNPC1RAB9A | |
| SCHEMBL10441226 | 0.75 | AOC3 (0.42) | AOC3ALDH1A1CYP3A4CYP2C9TSHR | |
| SCHEMBL6155692 | 0.74 | HRH4 (0.42) | HRH3 | |
| SCHEMBL5584506 | 0.72 | AOC3 (0.40) | AOC3ALDH1A1SLC6A3SLC6A4NPC1 | |
| SCHEMBL73543 | 0.72 | AOC3 (0.47) | AOC3ALDH1A1CA2SLC6A3SLC6A4 | |
| SCHEMBL5598283 | 0.72 | BCHE (0.43) | ALDH1A1NPC1RAB9A | |
| SCHEMBL5382942 | 0.70 | METTL3 (0.43) | AOC3CYP2C9CYP2C19 | |
| SCHEMBL5109119 | 0.68 | KDM4E (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160050895-A1 | TRANSGENIC NON-HUMAN ORGANISMS WITH NON-FUNCTIONAL TSPO GENES | THE UNIVERSITY OF SYDNEY (AU) | 2016-02-25 | — | — | US | disclosed |
| CN-102770425-A | Indolyl-piperidinylbenzylamines as beta-tryptase inhibitors | SANOFI SA | 2012-11-07 | — | — | CN | disclosed |
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| US-7189741-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA S.A. (ES) | 2007-03-13 | — | — | US | disclosed |
| EP-1330453-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2006-03-29 | — | — | EP | disclosed |
| US-20040116471-A1 | Indolylpiperidine derivatives as antihistaminic aand antiallergic agents | ALMIRALL PRODESFARMA S.A. (ES) | 2004-06-17 | — | — | US | disclosed |
| EP-1330453-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036589-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA S.A. (ES) | 2002-05-10 | — | — | WO | disclosed |
| US-20010053783-A1 | Central nervous system disorders | FAIRHURST JOHN (GB) | 2001-12-20 | — | — | US | disclosed |
| EP-0854146-B1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | LILLY CO ELI (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998031686-A1 | SUBSTITUTED 4-(6-FLUORO-(1H)-INDOL-3-YL)-1,2,3,6-TETRAHYDROPYRIDINE FOR THE TREATMENT OF CNS-DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-23 | — | — | WO | disclosed |
| EP-0854146-A1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-22 | — | — | EP | disclosed |
| US-3980658-A | SEDATIVES, TRANQUILIZERS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-09-14 | — | — | US | disclosed |
| US-3980658-A | SEDATIVES, TRANQUILIZERS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | AOC3 932/4885ALDH1A1 752/4885CYP3A4 939/4885 |
| US-20010053783-A1 | Central nervous system disorders | CNR1, PMP22, CNR2 | AOC3 934/4885ALDH1A1 491/4885CYP3A4 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.